Toxin and Immunotoxin Based Therapeutic Approaches

• Muut tekijät: Bortolotti, Massimo (Toimittaja), Polito, Letizia (Toimittaja), Bolognesi, Andrea (Toimittaja)
• Aineistotyyppi: Elektroninen Kirjan osa
• Kieli: englanti
• Julkaistu: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
• Aiheet: Humanities; Social interaction; 3D structure; plant toxin; primary sequence; ribosome-inactivating protein; stenodactylin; toxic lectin; fusion proteins; ricin; pokeweed antiviral protein; COVID-19; SARS-CoV-2; antiviral agent; ribosome-inactivating proteins; monoclonal antibody; immunotoxin; antibody drug conjugate; immunoliposome; drug delivery; diphtheria toxin; DT3C; prostate cancer; targeted toxins; epidermal growth factor; epidermal growth factor receptor; Pseudomonas Exotoxin A; patient-derived glioblastoma cell lines; Chenopodium quinoa wild; quinoin; temozolomide; Glypican-3; hepatocellular carcinoma; humanized YP7; new recombinant immunotoxin; kirkiin; sugar specificity; cancer therapy; n/a
• Linkit: DOAB: download the publication; DOAB: description of the publication

In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich's insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied anti...